BioSpace News Archive

Dermavant to Present Data from Multiple Clinical Trials of VTAMA ® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference.

Axcella Therapeutics today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of common stock (the “Shares”) at a purchase price of $1.64 per share, resulting in gross proceeds of $34.2 million.

Veru Inc. today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate to severe COVID-19 patients who required supplemental oxygen has been accepted as a late-breaker oral presentation at the upcoming IDWeek (Infectious Disease Week) 2022 taking place October 19-23, 2022.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company’s Biomark™ family of systems and its Juno™ system in NMPA molecular diagnostics services.

Today, Neurophth Therapeutics, Inc. has a special interview with Dr. Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology Society, to understand his perspectives on LHON.

Novavax, Inc. today announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate.

Epic Bio today announced a presentation on the company’s unique engineering platform, called the Gene Expression Modulation System (GEMS), at the co-hosted Solebury / BMO Fall Private Company Showcase.

LifeMine Therapeutics Inc. today announced the appointment of Jennifer Jarrett to its board of directors.

Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the RNA Leaders USA Congress being held on October 18-19, 2022 at The Colonnade Hotel in Boston, Massachusetts.

Carmine Therapeutics (“Carmine”), an EVX founded biotech company and emerging leader in non-viral gene therapies, today announced the first Closing of its Series A financing.